| Literature DB >> 26101557 |
Na Zhang1, Lingyan Wang1, Qi Duan1, Laixiang Lin2, Mohamed Ahmed1, Tingting Wang1, Xiaomei Yao1.
Abstract
PURPOSE: We aim to figure out the effect of metallothioneins on iodide excess induced oxidative stress in the thyroid.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26101557 PMCID: PMC4458558 DOI: 10.1155/2015/267027
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Oxidative and antioxidative effect of high concentrations of KI on the mitochondria of thyrocytes in MT-I/II KO mice and WT mice. (a) Decreased relative viability induced by high concentrations of KI (10−4 M, 10−3 M, and 10−2 M) or 10−3 M H2O2 in the thyroid cells of MT-I/II KO mice by MTT assay (N = 8). (b) Representative western blot of Prx 3 (27 kDa), β-actin (45 kDa) was used as a loading control. Densitometric analysis showed a significant increase (* P < 0.05) in Prx 3 expression compared to untreated control in the thyroid cells of either WT or MT-I/II KO mice. (c) Increased LDH release following 2 h of high concentration of KI or H2O2 exposure in the thyroid cells of MT-I/II KO mice (N = 8). (d) High concentration of KI or H2O2 induced increased mitochondrial superoxide production in the thyroid cells of WT and MT-I/II KO mice. Histogram analysis was performed on the mean fluorescence intensity of MitoSOX Red as measured by flow cytometry. Experiments were repeated 3 times with similar results. Data are represented as mean ± SD. One-way ANOVA with the LSD test was used. * P < 0.05 compared with the control group of WT or MT-I/II KO mice, respectively; # P < 0.05 WT mice versus MT-I/II KO mice under the same treatment.
The median urinary iodine concentrations (µg/L) of WT mice and MT-I/II KO mice.
| Group | WT | MT-I/II KO |
|---|---|---|
| NI | 320.29 ± 112.16 | 424.33 ± 131.95 |
| 10 HI | 3592.92 ± 519.98* | 3949.24 ± 647.93* |
| 100 HI | 30479.17 ± 4128.94* | 40666.35 ± 3520.46∗# |
*Compared to the NI group (P < 0.05); #WT mice group compared to MT-I/II KO mice group (P < 0.05). N = 10 for each group.
Changes of serum thyroid hormones level (nmol/L) in WT and MT-I/II KO mice following NI, 10 HI, or 100 HI intake for 14 days.
| Group | T3 | T4 | FT3 | FT4 |
|---|---|---|---|---|
| WT | ||||
| NI | 0.72 ± 0.13 | 26.08 ± 14.21 | 4.80 ± 0.42 | 28.56 ± 4.51 |
| 10 HI | 0.53 ± 0.09 | 33.50 ± 4.45 | 4.26 ± 0.41 | 31.42 ± 0.95 |
| 100 HI | 0.71 ± 0.13 | 34.70 ± 13.24 | 4.61 ± 0.25 | 33.20 ± 4.55 |
| MT-I/II KO | ||||
| NI | 0.58 ± 0.15 | 20.05 ± 4.68 | 4.04 ± 0.77 | 25.69 ± 0.97 |
| 10 HI | 0.69 ± 0.13 | 22.53 ± 7.79 | 4.78 ± 0.05 | 27.22 ± 1.03 |
| 100 HI | 0.80 ± 0.22 | 17.73 ± 6.76 | 5.01 ± 0.73 | 23.99 ± 1.92* |
*In 100 HI group, compared to WT mice, there was a significant difference in serum thyroid hormones level (FT4) in MT-I/II KO mice (P < 0.05). N = 8 for each group.
Figure 2Mitochondrial superoxide production, Prx 3 protein expression, and LDH release and relative viability in the thyroid of WT and MT-I/II knockout mice following NI, 10 HI, or 100 HI diet for 14 days. (a) 100 HI intake decreased the relative viability in thyroid of MT-I/II KO and WT mice. (b) Representative western blot of Prx 3 (27 kDa), β-actin (45 kDa) was used as a loading control. Densitometric analysis showed a significant increase in Prx 3 expression in 100 HI group in the thyroid of either WT or MT-I/II KO mice, especially in MT-I/II KO mice. (c) 100 HI increased the LDH release in the thyroid of MT-I/II KO and WT mice. (d) 100 HI intake increased the mitochondrial superoxide production in thyroid of WT and MT-I/II KO mice. Histogram analysis was performed on the mean fluorescence intensity of MitoSOX Red as measured by flow cytometry. Experiments were repeated 3 times with similar results. Data are represented as mean ± SD (N = 10/group). One-way ANOVA with the LSD test was used. * P < 0.05 compared with the control group of WT or MT-I/II KO mice, respectively; # P < 0.05 WT mice compared with the MT-I/II KO mice under the same treatment.
Documented literatures of iodide intake and changes of serum thyroxine (T4) and triiodothyronine (T3) concentrations.
| Dosage of daily iodine intake | Time | Subject | Changes of serum T4, T3 concentrations | Reference |
|---|---|---|---|---|
| 250 or 500 | 14 days | Normal volunteers | No change | [ |
|
| ||||
| 1500 | 14 days | Normal volunteers | T4, T3 ↓ TSH ↑ | [ |
|
| ||||
| 50 or 250 mg | 13 days | Normal subjects | T4, T3 ↓ TSH ↑ | [ |
|
| ||||
| 27 mg | 4 weeks | Normal volunteers | T4 within the normal range except for two subjects TSH ↑ | [ |
|
| ||||
| Single doses of 10, 30, 50, and 100 mg and then daily doses of 10, 15, 30, 50, or 100 mg | 12 days | Euthyroid volunteers | T3, T4 ↓ TSH ↑ | [ |
|
| ||||
| 190 mg | 10 days | Euthyroid volunteers | T3, T4 ↓ TSH ↑ | [ |
|
| ||||
| 114 mg | 3–7 weeks | Normal controls | T3, T4 ↓ TSH ↑ | [ |
|
| ||||
| 114 mg | 3–7 weeks | Thyrotoxic patients | T4, T3 ↑ in some cases; | [ |
|
| ||||
| 114 mg | 2 weeks | Hypothyroid patients on thyroxine replacement | No consistent change | [ |